ArticleFrontiers in oncology2024

Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms.

Sivahari P Gorantla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.